The U.S. Food & Drug Administration (FDA) Opioid Policy Steering Committee held a public hearing Tuesday, January 30, 2018, on “Prescribing Intervention – Exploring a Strategy for Implementation.”

    Steve Mullenix, R.Ph., NCPDP's Senior Vice President of Industry Relations and Public Policy, testified before the committee regarding NCPDP’s Recommendations for an Integrated, Interoperable Solution to Ensure Patient Safe Use of Controlled Substances

    NCPDP was among 33 organizations represented at the public hearing, including the American Medical Association, Health IT Now, National Association of Boards of Pharmacy, Academy of Managed Care Pharmacy, Adapt Pharma, individual patients, patient advocates and technology companies. The afternoon session was also attended by FDA Commissioner, Scott Gottlieb, M.D.

For problems with the site please contact us at